Peter Martin, MD
First-line therapy for patients with mantle cell lymphoma (MCL) must be administered in an individualized approach based on patient and disease characteristics, according to Peter Martin, MD.
Peer discussions held during the PER Medical Crossfire: Hematologic Malignancies meeting show several controversies in frontline management, including the difference in therapies that should be used in patients who are younger or older. Physicians do agree, however, that younger patients respond better to intensive therapy than older patients and that BTK inhibition should be used as a second-line therapy.
... to read the full story